Nisevokitug

尼斯奇塔单抗

Report date: 2026/05/20 20:02:01

Base Information

Drug NameNisevokitug
Drug Alias NameAnti-TGF beta antibody (Novartis)Nisevokitug (Novartis)NIS-793
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTransforming growth factor beta 1 inhibitorsTransforming growth factor beta 2 inhibitors
TargetsTransforming growth factor beta 1Transforming growth factor beta 2
Therapy Area/IndicationsPrimary MyelofibrosisMyelodysplastic SyndromesThrombocythemia, Essential +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[29] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesXoma Corp
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma AgNovartis Pharma Stein AgLonza AG +[4] 
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesKidney NeoplasmsLung Neoplasms +[8] 
Inactive IndicationsPrimary MyelofibrosisThrombocythemia, EssentialPolycythemia Vera +[4] 

Other Information

ATC CodeN/A
Related LinksN/A